SIGMAR1 and amyotrophic lateral sclerosis: Studies testing two other Sig-1R agonists, SA4503 and pridopidine, also showed that treatment ameliorates ALS pathology (Ionescu et al., 2019; Ono et al., 2014), and pridopidine is being tested in a clinical trial for ALS (ClinicalTrials.gov NCT04615923).